•Glaukos and RevOpsis partner on retina tri-specific therapy development, commercialization•Dexamethasone eye drops may cut invasive ROP treatment in preterm infants•Nacuity doses first patient in phase 3 trial on oral therapy for RP associated with Usher syndrome•Simple OCT rule helps cut glaucoma false positives in myopia•EyeDock debuts AI clinical assistant for ECPs•Glaukos and RevOpsis partner on retina tri-specific therapy development, commercialization•Dexamethasone eye drops may cut invasive ROP treatment in preterm infants•Nacuity doses first patient in phase 3 trial on oral therapy for RP associated with Usher syndrome•Simple OCT rule helps cut glaucoma false positives in myopia•EyeDock debuts AI clinical assistant for ECPs
HEADLINES
FEATURED
Company positions HarrowRx as a first-of-its-kind platform in the U.S. bringing prescribing, fulfillment, and patient support into one place for its entire branded portfolio.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
